ClinicalTrials.gg
RecruitingNCT07855237CADNATUpdated Nov 2, 2026

Cadmium Exposure During Pregnancy and Fetal Growth

An observational study in Cadmium, Placenta and Fetal Growth, sponsored by Centre Hospitalier Universitaire, Amiens. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Centre Hospitalier Universitaire, Amiens · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 2, 2026Primary outcomes revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
Female
01

Study summary

Cadmium is a toxic heavy metal naturally present in the environment, whose human exposure has increased over recent decades due to diffuse anthropogenic contamination, particularly related to industrial activities and the use of mineral phosphate fertilizers in agriculture.

Cadmium is characterized by its bioaccumulative properties and well-established toxicity, including renal and bone damage and carcinogenic effects. In pregnant women, several animal and human cohort studies have shown that cadmium can cross the placental barrier and accumulate in placental tissue. Placental cadmium exposure has been associated with impaired placental function and adverse perinatal outcomes, including fetal growth restriction and increased neonatal morbidity. In the general population without occupational exposure, diet represents the main source of cadmium exposure, apart from tobacco smoking. Fetal growth, commonly assessed through birth weight adjusted for gestational age, is a major determinant of neonatal and long-term health outcomes. This monocentric prospective pilot study aims to assess fetal exposure to cadmium during pregnancy using placental cadmium concentration as a biomarker. Placental samples will be collected at delivery from women giving birth at Amiens University Hospital, and cadmium levels will be measured using inductively coupled plasma mass spectrometry. The association between placental cadmium concentration and fetal growth will be explored. Fetal growth will be evaluated using birth weight adjusted for gestational age, expressed as a standardized z-score. Maternal urinary and blood cadmium concentrations will also be measured to characterize maternal exposure and explore correlations between biological matrices. Placental efficiency, defined as the fetal-to-placental weight ratio, will be assessed as an indicator of placental function. The results of this pilot study will provide preliminary data to inform future larger-scale epidemiological and mechanistic studies on prenatal cadmium exposure and pregnancy outcomes.

02

Conditions studied

  • Cadmium
  • Placenta
  • Fetal Growth
  • Birth Weight
  • Environmental Exposure

Browse trials for

Keywords

  • biomonitoring
  • environmental exposure
  • birth weight
  • fetal growth
  • Placenta
  • Cadmium
03

In context

Birth Weight

185 studies on the registry are indexed under Birth Weight; 24 are open to participants now.

This study's planned enrollment of 50 is below the median of 240 across 63 observational studies indexed under Birth Weight.

Browse Birth Weight studies →

Lead sponsor

Centre Hospitalier Universitaire, Amiens is the lead sponsor of 586 studies on the registry; 185 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women delivering at term or preterm who are patients at Amiens University Hospital,

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women aged 18 years or older
  • Singleton pregnancy
  • Planned delivery at the maternity unit of Amiens University Hospital (CHU Amiens)
  • Ability to receive study information and provide informed non-opposition/consent according to French regulations for non-interventional research

Exclusion criteria

Exclusion Criteria:

  • Women under legal protection measures, including guardianship, curatorship, or judicial safeguard
  • Inability to understand the study objectives or the constraints of the protocol (language barrier, cognitive impairment, or other reasons)
  • Lack of affiliation to a social security system, as required by French regulations
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
2 Months
Patient registry
Yes
Biospecimen retention
Samples without dna

Interventions

  • Othermaternal blood samples

    maternal blood samples are collected at admission for delivery as part of standard obstetric care.

  • OtherPlacental tissue samples

    Placental tissue samples are collected at delivery,

  • Othermaternal urine samples

    maternal urine samples are obtained during routine prenatal visits,

06

What researchers measure

Primary outcomes

  1. association between placental cadmium levels and fetal growth

    investigate the correlation between placental cadmium levels and fetal growth.

    Time frame: at 2 months

Secondary outcomes

  1. association between maternal urinary cadmium concentration and fetal growth

    Correlation between maternal urinary cadmium concentration (adjusted for creatinine) and fetal growth, assessed by birth weight adjusted for gestational age (z-score).

    Time frame: at 2 months

  2. Association between maternal blood cadmium concentration and fetal growth

    Association between maternal blood cadmium concentration and fetal growth, assessed by birth weight adjusted for gestational age (z-score).

    Time frame: at 2 months

  3. Association between placental cadmium concentration and placental efficiency

    Association between placental cadmium concentration and placental efficiency, defined as the fetal-to-placental weight ratio

    Time frame: at 2 months

  4. Association between maternal dietary patterns and estimated dietary cadmium intake and cadmium concentrations measured in placental tissue

    Association between maternal dietary patterns and estimated dietary cadmium intake and cadmium concentrations measured in placental tissue

    Time frame: at 2 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Nov 2026, 2 months after the start.

Of 33 non-industry observational studies under Birth Weight, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 52. This study's planned 2 months is below that.

Counting every sponsor, half of 34 studies reached it within 25 months; a quarter within 10 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartActual
Sep 21, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 description edited
What changed in the outcomes
  • Descriptionassociation between placental cadmium levels and fetal growth: how it is measured was reworded
Nov 2, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedAssociationassociation between maternal urinary cadmium concentration and fetal growthTime frame: at 2 months
Nov 2, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 2 updates
  1. Nov 2, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • Descriptionassociation between placental cadmium levels and fetal growth: how it is measured was reworded
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedAssociationassociation between maternal urinary cadmium concentration and fetal growthTime frame: at 2 months
    + 1 other change: conditions
  2. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07855237
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Sep 21, 2026
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 2, 2026

Study contacts

Rosalie CABRY, Pr
Contact
cabry.rosalie@chu-amiens.fr
33+3 22 08 73 70

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion